New way of wiring pacemakers cut serious heart problems by 59%
In the OptimPacing trial of 685 people with heart block, pacing through the heart's own left bundle branch cut deaths, heart failure admissions and pacemaker-related heart weakening.

Contents
People with heart block who were given a pacemaker wired into the heart's own left bundle branch had 59% fewer serious problems than people paced in the usual way, in the OptimPacing trial published in the New England Journal of Medicine on 8 November 2026. Those problems were death, a hospital stay for heart failure, or the pacemaker itself weakening the heart muscle.
The result was presented the same day at the American Heart Association's Scientific Sessions 2026 in Chicago. An independent data monitoring committee had already recommended stopping the trial early, because the newer approach crossed a pre-set threshold for superiority at a planned interim look.
By four years, an estimated 8.5% of patients in the left bundle branch pacing group had died, been admitted with heart failure or developed pacing-induced cardiomyopathy. The figure in the standard right ventricular pacing group was 19.2%. The hazard ratio was 0.41, with a 95% confidence interval of 0.23 to 0.75.
Most of that gap came from one outcome. No one in the left bundle branch group developed pacing-induced cardiomyopathy, against an estimated 11.7% of the right ventricular group, according to the American Heart Association's news release. Deaths from any cause were similar in the two groups, the AHA's meeting summary said.
What heart block is and why it needs a pacemaker
The heart's upper chambers (the atria) send an electrical signal down to the lower chambers (the ventricles) with every beat. In atrioventricular block, usually shortened to AV block or heart block, that signal is delayed or stopped on the way. The NHS page on heart block describes three degrees of severity. The more serious forms can cause a very slow pulse, tiredness, dizziness and fainting.
A pacemaker fixes the slow rate. It sits under the skin below the collarbone and sends small electrical pulses down one or more leads into the heart whenever the heart's own signal fails to arrive. For decades the ventricular lead has been screwed into the muscle of the right ventricle, either at its tip (the apex) or on the wall between the two ventricles (the septum). The NHS guide to pacemaker implantation covers what the operation involves.
Right ventricular pacing works well for its main job. People with complete heart block who need it are protected from dangerously slow rhythms. The drawback is how the beat spreads. A pulse delivered into right ventricular muscle travels slowly from cell to cell, so the right side contracts first and the left side follows late. In some people who are paced most of the time, that out-of-step squeeze slowly weakens the left ventricle. Doctors call this pacing-induced cardiomyopathy, and it can lead to heart failure.
How left bundle branch pacing is different
The heart already has its own fast wiring. Specialised fibres, the His bundle and then the left and right bundle branches, carry the signal quickly through both ventricles so they contract together. Conduction system pacing puts the pacemaker lead into that wiring.
In left bundle branch pacing, the doctor screws a thin lead deeper into the septum from the right side until its tip reaches the area of the left bundle branch. Paced beats then travel through the left ventricle along the natural route. Jiangang Zou, the trial's lead investigator and a professor of cardiology at the First Affiliated Hospital of Nanjing Medical University, put it this way in the AHA release: "Our findings show that left bundle branch pacing helped the heart beat in a more natural way and was linked to fewer serious heart-related events than the standard pacing approach of right ventricular pacing."
The technique is not new to cardiologists. In the United States, the FDA approved a labelling change for Medtronic's SelectSecure MRI SureScan Model 3830 lead in October 2022, adding pacing in the left bundle branch area as an alternative to right ventricular pacing. That decision rested on real-world evidence. What was missing until now was a large randomised trial with hard clinical outcomes, and OptimPacing is the first to report one for heart block.
Who was in the OptimPacing trial
OptimPacing was an investigator-led study sponsored by the First Affiliated Hospital with Nanjing Medical University and registered on ClinicalTrials.gov as NCT04624763. It ran at 17 centres in mainland China, Hong Kong, the United Kingdom, Poland and the United States between June 2021 and January 2025.
Adults qualified if they needed a permanent pacemaker for second-degree or complete AV block, or had persistent or permanent atrial fibrillation with a slow average heart rate below 50 beats per minute. The NEJM paper reports that 702 people were randomised and 685 made it into the main analysis after 17 dropped out before their device was fitted. That left 342 in the left bundle branch group and 343 in the right ventricular group.
The average age was 68.4 years and 57.5% were men. Hearts were pumping normally at the start for most patients. The AHA's late-breaking science summary gives a mean left ventricular ejection fraction of 63.2% in the left bundle branch group and 62.5% in the right ventricular group. Every left bundle branch procedure used the same lumenless 3830 lead.
The main outcome combined three events: death from any cause, hospital admission for heart failure, and pacing-induced cardiomyopathy. Medscape's conference report gives the trial's definition of that last one: a fall in ejection fraction of at least 10 percentage points to below 50%, with no other cause found.
The results in numbers
The interim analysis was triggered after 51 primary events, at a median follow-up of 35.1 months. Here is how the two groups compared, using figures from the NEJM abstract and the AHA release.
| Outcome | Left bundle branch pacing | Right ventricular pacing |
|---|---|---|
| Patients with a primary event | 16 | 35 |
| Estimated four-year rate of the primary outcome | 8.5% | 19.2% |
| Pacing-induced cardiomyopathy | 0% | 11.7% |
| Hospital admission for heart failure | 1.5% | 2.9% |
| Serious adverse events not linked to the implant | 11.8% | 9.3% |
The difference in serious adverse events unrelated to the implant procedure was not statistically significant (P = 0.32). The AHA summary says rates of procedure and pacing-system complications, and of lead revisions, were similar.
Some of the device data helps explain why the outcomes split. Medscape reported that the paced QRS complex, a measure of how long the ventricles take to activate, averaged 124 milliseconds with left bundle branch pacing and 151.7 milliseconds with right ventricular pacing. Shorter means more coordinated. More than 90% of beats were paced in both groups, so nearly everyone in the trial depended heavily on their device.
The left bundle branch approach did not always work. Eleven patients assigned to it could not have the lead placed successfully and were switched to right ventricular pacing, and left bundle branch capture was confirmed in 87.6% of the group, according to Medscape's account of the presentation. Those patients stayed in their original group for the main analysis.
A worked example in absolute terms
A 59% lower relative risk sounds large. Absolute numbers give a clearer sense of what it could mean for a group of patients.
Using the estimated four-year rates, 19.2% minus 8.5% is 10.7 percentage points. Dividing 100 by 10.7 gives about 9.3. In plain terms, for every nine or ten people with heart block like those in this trial who were paced through the left bundle branch, one fewer would be expected to have one of the three primary events within four years.
That calculation comes with caveats. The rates are Kaplan-Meier estimates from a trial that stopped early, and nearly all of the benefit came from avoided cardiomyopathy, which is diagnosed partly on heart scans. Our guide to reading clinical trial results and absolute risk goes through these measures step by step.
Limits the investigators flagged
The researchers listed their own weak points, and each one shapes how far the result can be pushed.
Trials stopped early for benefit tend to overstate the size of the effect, because they halt at a moment when the gap between groups happens to look wide. The true benefit may be smaller than 59%.
Patients and doctors knew which pacing method was used. This was an open-label trial, since the lead position shows up on every ECG. The AHA release says major health events were judged by a committee that did not know the treatment group. Medscape, though, reported that some echocardiograms were missing and that reading bias was possible. That matters most for cardiomyopathy, the outcome that drove the result. Our explainer on open-label and blinded trials covers why this design choice is common in device studies.
Most participants started with normal pumping function, so the findings may not apply to people whose hearts are already weakened. Only one type of lead was used. And deaths were similar between groups, so the trial does not show that the newer method helps people live longer.
Where this leaves guidelines and practice
The 2023 HRS, APHRS and LAHRS guideline on cardiac physiologic pacing already says that patients expected to need a substantial amount of ventricular pacing, which it defines as 20% to 40% or more, may be considered for physiologic pacing to cut the risk of pacing-induced cardiomyopathy. That was a cautious recommendation built mostly on observational studies.
OptimPacing adds randomised outcome data to that mostly observational evidence. Zou said in the AHA release that the trial "shows that left bundle branch pacing should be the first choice for patients with heart block who need a pacemaker." He also said more research is needed to work out which technique suits which patients, to compare different forms of conduction system pacing, and to look at long-term safety and cost.
OptimPacing does not settle how quickly the technique should become routine. Every left bundle branch procedure in the trial used one lead type, and 11 patients could not have it placed in the left bundle branch area. If you are due a pacemaker, ask your implanting team whether they offer this approach and how often they use it.
For other recent heart trials we have covered, see early TAVR in moderate aortic stenosis, tricuspid valve repair in heart failure and anticoagulation after a single episode of AF.
Questions to ask before a pacemaker is fitted
If you or a relative has been told you need a pacemaker for heart block, these questions can help you understand the plan:
- How much of the time is my heart expected to rely on the pacemaker?
- Does this hospital offer left bundle branch or other conduction system pacing, and how many has the team done?
- What is my current ejection fraction, and will it be checked again after the implant?
- If the lead cannot be placed in the left bundle branch area, what is the fallback?
- How often will my heart function be monitored over the years?
The British Heart Foundation's pacemaker pages explain recovery and day-to-day life with a device. If you are interested in pacing research, our guide to finding and joining a clinical trial shows how to search the registries.
This article reports trial results for general information. It is not medical advice, and decisions about pacemaker type should be made with a cardiologist or electrophysiologist who knows your history.
Frequently asked questions
What is left bundle branch pacing?
It is a way of fitting a pacemaker lead so that it stimulates the left bundle branch, part of the heart's own fast electrical wiring. The lead is screwed through the wall between the two ventricles from the right side. Paced beats then spread through the left ventricle along the natural route, so both lower chambers contract more in step than they do with standard right ventricular pacing.
Does left bundle branch pacing help people live longer?
OptimPacing did not show that. Deaths from any cause were similar in the two groups. The 59% lower risk was for a combined outcome of death, heart failure admission and pacing-induced cardiomyopathy, and most of the difference came from cardiomyopathy. No one in the left bundle branch group developed it, against an estimated 11.7% of patients given standard pacing.
Is left bundle branch pacing available in the UK?
The trial ran at 17 centres, and the United Kingdom was one of the five countries taking part. OptimPacing does not change national guidance overnight. Whether you are offered this method depends on your type of heart block, how much pacing you are expected to need, your heart function and the experience of your implanting team, so ask them directly before the procedure is booked.
I already have a standard pacemaker. Should I have it changed?
The trial only compared methods in people having a new pacemaker fitted, so it gives no evidence for swapping a working system. Leads are not usually changed without a clear reason, because extra procedures carry their own risks. If you have symptoms such as new breathlessness, or a scan shows your heart pumping less well, raise it with your device clinic.
Why was the OptimPacing trial stopped early?
At a planned interim analysis after 51 primary events, the independent data monitoring committee found that left bundle branch pacing had met the trial's pre-set threshold for superiority, and it recommended ending the study. The investigators note that stopping early can overstate the benefit, so the true reduction in risk may be smaller than the 59% reported.
Sources
- Left Bundle-Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block. New England Journal of Medicine, 2026-11-08
- Novel pacemaker technique reduced cardiac events in people with a heart rhythm disorder. American Heart Association, 2026-11-08
- Latest innovations designed to optimize arrhythmia care. American Heart Association Scientific Sessions, 2026-11-13
- OptimPacing: Left Bundle-Branch Pacing vs. Right Ventricular Pacing For Atrioventricular Block. American College of Cardiology, 2026-11-08
- Left Bundle Branch Outperforms Right Ventricle for Pacing. Medscape, 2026-11
- Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block (OptimPacing), NCT04624763. ClinicalTrials.gov, 2026
- 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm Society, 2023
- Premarket Approval P030036/S139, Medtronic SelectSecure MRI SureScan Lead. US Food and Drug Administration, 2022-10-03
- Heart block. NHS, 2026
- heart block
- pacemaker
- conduction system pacing
- OptimPacing
- NEJM
- cardiology
- atrioventricular block
- left bundle branch pacing
- pacing-induced cardiomyopathy
- AHA 2026
Medical disclaimer: For information only, not medical advice. Speak to a qualified healthcare professional about your care.
The Briefing
Trial results that matter, every Friday.
One email. The week's readouts, approvals and research, explained without hype.
Related reading
Drug cut Lp(a) cholesterol by 78% yet heart attacks did not fall
7 November 2026
CardiologyQuarterly jab cut pancreatitis attacks in very high triglycerides
4 November 2026
CardiologyEarly TAVR cut heart failure events in moderate aortic stenosis
2 November 2026
Lung artery nerve procedure halves worsening in heart failure
30 August 2026